Eton Pharmaceuticals, Inc.
ETON
$58.86
$18.0644.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.89% | 104.94% | 102.77% | 85.40% | 40.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.89% | 104.94% | 102.77% | 85.40% | 40.88% |
| Cost of Revenue | 85.08% | 105.87% | 116.32% | 67.27% | 63.36% |
| Gross Profit | 76.54% | 104.32% | 93.48% | 97.75% | 29.42% |
| SG&A Expenses | 38.56% | 57.75% | 61.40% | 54.88% | 40.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.16% | 82.36% | 72.72% | 49.31% | 45.24% |
| Operating Income | 1,075.07% | 321.40% | 127.00% | 131.18% | -231.00% |
| Income Before Tax | 66.94% | -19.70% | -22.18% | 36.94% | -487.50% |
| Income Tax Expenses | -112.36% | 186.67% | 13.71% | -66.45% | -63.97% |
| Earnings from Continuing Operations | 67.82% | -20.35% | -21.91% | 38.27% | -602.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.82% | -20.35% | -21.91% | 38.27% | -602.08% |
| EBIT | 1,075.07% | 321.40% | 127.00% | 131.18% | -231.00% |
| EBITDA | 812.35% | 956.66% | 216.77% | 187.82% | -18.07% |
| EPS Basic | 68.21% | -15.52% | -17.05% | 40.95% | -580.00% |
| Normalized Basic EPS | 210.30% | 131.35% | 56.68% | 81.29% | -347.04% |
| EPS Diluted | 62.19% | -13.62% | -18.44% | 35.86% | -614.52% |
| Normalized Diluted EPS | 185.96% | 117.92% | 56.78% | 81.10% | -362.73% |
| Average Basic Shares Outstanding | 3.16% | 3.89% | 3.51% | 2.73% | 1.83% |
| Average Diluted Shares Outstanding | 10.66% | 7.38% | 2.87% | 3.36% | 2.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |